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PERHAPS I should start by saying that lowe my share 
of this prize to the people with whom I have worked. 
and especially to the patients who allowed us to treat them. 
I came into transplantation through the back door of 
physiology, during metabolic investigations of portal phys-
iology in the mid-1950s. By 1959, we had clarified the 
surgical secrets of liver transplantation.' These were (I' 
the hepatotrophic (liver-supporting) superiority of portal 
venous blood that was required for revascularization: m 
the need for core cooling of the liver graft as is practiced 
today as the first step in the preservation of all organs; and 
0) the use of a venovenous bypass during the an hepatic 
period. Unknown to us at first. Francis D. Moore's team in 
Boston had begun similar liver transplant research at the 
same time and had come to many of the same conclu-
sions.: Our work on liver transplantation was finished by 
the end of 1959. as was a second project in dogs on 
multivisceral transplantation,) which 25 years later was 
performed successfully i"\humans and was the basis for 
several variations, such .f6 cluster and liver-intestine 
transplantations. 4 
This activity in 1958 through early 1960 was in a thera-
peutic vacuum because there was no such thing as practi-
cal immunosuppression. The ~assical paper on 6-mercap-
topurine by Schwartz and Dameshek5 in nontransplant 
models and its testing in skin and kidney transplant mod-
elsf>KK~ were published toward the end of this period. 
Realizing by now that the road to the liver would have to 
be through the simpler kidney transplant model, I moved 
from Northwestern University in Chicago to the Univer-
sity of Colorado in 1961 in order to begin a clinical kidney 
program. 
The Colorado kidney program was based on the simple 
laboratory discovery that canine kidney rejection under 
azathioprine could be reversed with prednisone in 88% of 
dogs. a rate that proved to be the same in humans. '0 
Neither azathioprine nor adrenal cortical steroids in dogs 
or humans allowed kidney transplantation to be performed 
at a pmctlcallevel." but the drug combination became the 
basis for a clinical specialty and led to two further initia-
tives. both of which failed. The first was liver transplanta-
tion. which wa~ technically successful in two of the first 
three cases.': but resulted in death in all patients. The 
second initiative was baboon-to-human kidney xenotrans-
plantation." following Reemtsma's pathfinding tnals with 
chimpanzee donors. 14 The baboon kidneys were rejected 
after 6 to 60 days. foreclosing further baboon trials for 
more than two decades. 
The liver program was itself closed for 4 more years of 
intensive further laboratory investigation. Then. in July 
1967, the first long-surviving liver recipients were pro-
duced '5 in a collaboration with Carl Groth of Stockholm. 
who was a key team member during this effort. which by 
now had consumed almost 10 years. Acceptance of the 
procedure was slow over the next dozen years because of 
its high mortality. Clinical liver transplantation became a 
curiosity. being performed by a few stubborn eccl'fltrics on 
both sides of the Atlantic. Roy Calne's introtluction of 
cyclosporine'6 allowed a tripling of survival about a dec-
ade ago and brought liver transplantation to center stage.'7 
Recently the liver has been the lead organ in understand-
ing the immunologic and metabolic terms of successful 
xenotransplantation. Following hamster-rat xenotrans-
plantation. the interstitial leukocytes that I discussed in my 
Presidential Address migrate ubiquitously (Fig I l. whereas 
the hepatocytes retain their donor metabolic specificity 
and recreate their own chemical environment. For exam-
ple. the serum proteins of the rat become those of the 
hamster within I week after xenotransplantation of a 
hamster liver (Fig 2). The hamster liver also brings its own 
coagulation profile. For one thing. the rat. which does not 
produce a supply of the natural anticoagulant. C protein. 
acquires the C protein and is "hamsterized" in other ways 
within days of receipt of a hamster liver. Yet. neither 
bleeding nor clotting were encountered. This observation 
provided the final assurance leading to a decision to 
proceed with a clinical trial. 
The same transition of serum proteins to that of the 
donor occurred in our human recipient of a baboon liver. 
The metabolic consequences are so wide-ranging that 
years will be required to study them completely. An 
example is serum uric acid. which is near zero in the 
normal baboon whose liver has well-developed enzyme 
systems for conversion of this metabolite. After xenotrans-
plantation of a baboon liver. there was virtual disappear-
ance of uric acid from the patient's serum. 
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Fig 1. Nature of chimerism after xenotransplantation. 
The baboon-to-human liver xenotransplantation was 
performed in Pittsburgh on June 28. 1992 (by Drs Andreas 
Tzakis. John Fung, and Satoru Todol. The recipient is a 
35-year-old man with end-stage chronic active hepatitis 
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Fig 2. Serum protein electrophoresis. Albumin. dark upper band 
(SPE kit, Beckman Instruments. Brea. CAl. 
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Fig 3. Course of patient after receipt of baboon liver. PGE. 
prostaglandin E. 
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caused by the B virus that is thought incapable of infecting 
the baboon liver. Baseline immunosuppression was with 
conventional doses of FK 506. prednisone. and prostaglan-
din E, essentially the same formula as our preferred 
therapy after hepatic allotransplantation (Fig 3). Cyclo-
phosphamide in nontoxic doses was added. based on the 
investigations by Murase et ai lM showing amelioration of 
the xenograft humoral rejection with this drug. Serious 
rejection has never been encountered. The patient's bili-
rubin is normal. 
A post perfusion biopsy of the baboon liver from a 
53-pound donor showed neutrophils in the sinusoids but no 
clinical evidence of hyperacute rejection. Twelve days 
later, the liver looked grossly normal and on biopsy 
showed a minor periportal cellular infiltrate. 
Although biopsies specimens taken at 12 and 24 days 
showed only minimal cellular rejection and were almost 
normal except for mild cholestasis. immunofluorescence at 
12 days showed extensive deposits of immunoglobulin M 
(lgM). which at 24 days had largely disappeared. The IgG 
followed the same pattern. Meanwhile. by day 24 the liver 
had regenerated to the appropriate size for the 170-pound 
recipient. 
The patient is well 53 days posttransplantation. We 
know that he has started the transformation to a state of 
mixed chimerism that we believe is integral to xenograft as 
well as allograft acceptance. At 35 days. blood chimerism 
was identified with baboon chorionic gonadotropin B sub-
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unit genes. Normal human blood has no baboon marker. 
but this patient has had a striking baboon band. estimated 
from dilution studies to be one baboon ceIJ/I.OOO human 
cells. 
It is too early to be sure. but it looks now as if the 
immune reaction to the baboon liver can be controlled 
without toxic immunosuppression. There do not appear to 
be serious metabolic incompatibilities with the baboon-
human species combination. There is no evidence yet of 
reinfection of the liver with B virus. If this resistance 
continues. there are implications for other viral infections 
with which baboons cells also cannot be infected. includ-
ing human immunodeficiency virus. 
Should this effort remain successful. it will be the 
vindication of yet another vision of Peter Medawar. who 
had a long interest in xenotransplantation. Almost 400 
years ago to the day. Galileo arrived to his faculty position 
at the University of Padova. Armed with a telescope. he 
began the inquiries that defined the mysterious universe 
and led to a walk on the moon. Our Galileo was Peter 
Medawar. whose first inquiries into the biologic meaning 
of rejection and the universe of transplantation took place 
12WiC of the time back to those medieval days. For me. 
there could be no greater honor than to receive a prize 
named Medawar. 
REFERENCES 
I. Starzl TE. Kaupp HA Jr. Brock DR. et al: Surg Gynecol 
Obstet 111:733. 1960 \ 
\ 
17 
2. Moore FD. Wheeler HB. Demissianos HV. et al: Ann Surg 
152:374. 1960 
3. Starzl TE. Kaupp HA Jr: Surg Forum 1\:28. 1960 
4. Starzl TE. Todo S. Tzakis A. et al: Surg Gynecol Obstet 
172:335. 1991 
5. Schwartz R. Dameshek W: Nature 183:1682. 1959 
6. Meeker W. Condie R. Weiner D. et al: Proc Soc Exp Bioi 
Med 102:459. 1959 
7. Schwanz R. Dameshek W: J Clin Invest 39:952. 1960 
8. CaIne RY: Lancet 1:417. 1960 
9. Zukoski CF. Lee HM. Hume DM: Surg Forum 11:470. 
1960 
10. Starzl TE. Marchioro TL. Waddell WR: Surg Gynecol 
Obstet 117:385. 1%3 
II. Murray JE. Memll JP. Harrison JH. et al: N Engl J Med 
~SU:1P1RK 1963 
12. Starzl TE. Marchioro TL. Von Kaulla KN. et al: Surg 
GynecolObslet 117:659. 1963 
13. Starzl TE. Marchioro TL. Peters GN. et al: Transplantation 
1:752. 1964 
14. Reemtsma K. McCracken BH. Schlegel JU. et a~-Ann Surg 
160:2:752. 1964 
15. Starzl TE. Groth CG. Brelt~chneider L. et al: Ann Surg 
168:392. 1968 
16. Caine RY. Rolles K. White DJG. et al: Lancet 2: 1033. 
1979 
17. Starzl TE. K lintmalm G BG. Porter KA. et al: N Engl ] Med 
305:266. 1981 
18. Murase N. Starzl TE. Demetris AJ. et al: Transplantation 
(in press) 
